ArticleFrontiers in immunology2026
Specific IgG levels before and one month after administration of a booster dose of the diphtheria, tetanus, and pertussis vaccine in 14-year-old adolescents.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The maintenance of durable humoral immunity against diphtheria, tetanus, and Bordetella pertussis during adolescence is critical for long-term protection and epidemiological stability. However, the immunological impact of booster vaccination at 14 years, particularly for pertussis, remains incompletely understood. Methods: In this prospective, open-label study, 121 healthy 14-year-old adolescents received booster vaccination with Td-M (n = 34), Tdap (n = 51), or Tdap-M (n = 36). Serum IgG antibodies against diphtheria and tetanus toxoids and B. pertussis were quantified by ELISA before and one month after vaccination. Humoral responses were assessed using geometric mean titers and established seroprotection thresholds. Results: At baseline, all participants exhibited protective immunity to tetanus, while a minority lacked protective antibody levels against diphtheria (1.7%) and pertussis (6.9%). Booster vaccination elicited a robust increase in anti-diphtheria IgG across all groups, with no significant differences between vaccine formulations. All adolescents achieved high levels of tetanus-specific antibodies, indicating strong anamnestic responses, with the highest titers observed in the Td-M group. In contrast, pertussis-specific IgG responses were heterogeneous and showed no overall increase following revaccination, suggesting limited booster-induced humoral expansion in previously primed individuals. Notably, Tdap-M maintained more stable antibody levels compared to Tdap. All vaccines demonstrated good tolerability with only mild adverse events. Conclusion: Adolescent booster vaccination effectively reinforces humoral immunity against diphtheria and tetanus, reflecting preserved immunological memory. However, the absence of a significant pertussis-specific IgG boost suggests that pre-existing immunity, potentially shaped by prior vaccination and natural exposure, may limit the measurable serological response. These findings question the immunological necessity of routine pertussis revaccination at 14 years and highlight the need for optimization of booster strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.